# Frespaciguat (MK-5475) in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)

> **NCT04425733** · PHASE1 · WITHDRAWN · sponsor: **Merck Sharp & Dohme LLC**

## Conditions studied

- Coronavirus Disease 2019 (COVID-19)
- Pneumonia
- Hypoxemia

## Interventions

- **DRUG:** Frespaciguat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04425733
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-07-07
- **Primary completion:** 2020-11-10
- **Final completion:** 2020-11-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04425733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04425733, "Frespaciguat (MK-5475) in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04425733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*